IDH2 and acute myeloid leukemia: In contrast to SPNGTIQNIL, we were able to detect the wildtype IDH2 peptide SPNGTIRNIL on patient-derived AML cells, which is in line with the stronger HLA-B*07:02 binding predicted for this peptide (Table S3).